Jorge Máspero

13.2k total citations · 5 hit papers
136 papers, 4.7k citations indexed

About

Jorge Máspero is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Jorge Máspero has authored 136 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Physiology, 54 papers in Pulmonary and Respiratory Medicine and 50 papers in Immunology and Allergy. Recurrent topics in Jorge Máspero's work include Asthma and respiratory diseases (116 papers), Allergic Rhinitis and Sensitization (49 papers) and Respiratory and Cough-Related Research (47 papers). Jorge Máspero is often cited by papers focused on Asthma and respiratory diseases (116 papers), Allergic Rhinitis and Sensitization (49 papers) and Respiratory and Cough-Related Research (47 papers). Jorge Máspero collaborates with scholars based in United States, Argentina and United Kingdom. Jorge Máspero's co-authors include James Zangrilli, Mario Castro, Michael E. Wechsler, Guy Brusselle, Eric D. Bateman, Philip G. Bardin, Kevin Murphy, Stephanie Korn, Christopher O’Brien and Neil M.H. Graham and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Jorge Máspero

129 papers receiving 4.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

2015 840 citations Mario Castro, James Zangrilli et al. The Lancet Respiratory Medicine profile →
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

2016 632 citations Mario Castro, Jonathan Corren et al. profile →
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

2021 258 citations Michael E. Wechsler, Ian Pavord et al. profile →
Type 2 inflammation in asthma and other airway diseases

2022 170 citations Jorge Máspero et al. profile →
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials

2025 17 citations Jorge Máspero et al. profile →

Peers

Countries citing papers authored by Jorge Máspero

Since Specialization

Citations

This map shows the geographic impact of Jorge Máspero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Máspero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Máspero more than expected).

Fields of papers citing papers by Jorge Máspero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Máspero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Máspero. The network helps show where Jorge Máspero may publish in the future.

Co-authorship network of co-authors of Jorge Máspero

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Máspero. A scholar is included among the top collaborators of Jorge Máspero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Máspero. Jorge Máspero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma 2025 ·Pediatric Pulmonology ·Leonard B. Bacharier, Jorge Máspero, Nikolaos G. Papadopoulos, Rémi Gagnon, Theresa W. Guilbert, (unknown), (unknown), Mena Soliman	0
2	Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma 2024 ·Journal of Allergy and Clinical Immunology ·Leonard B. Bacharier, Ian Pavord, Jorge Máspero, Daniel J. Jackson, Alessandro Fiocchi, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Elizabeth Laws, Leda Mannent, Nikhil Amin, Bolanle Akinlade, Heribert Staudinger, David J. Lederer, Megan Hardin	23
3	Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE) 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Jorge Máspero, Martti Antila, A. Deschildre, Leonard B. Bacharier, Arman Altincatal, Elizabeth Laws, (unknown), Amr Radwan, Juby A. Jacob‐Nara, (unknown), Paul J. Rowe, David J. Lederer, Megan Hardin	3
4	Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma 2023 ·Respiratory Medicine ·Jorge Máspero, Shirin Shafazand, Jeremy Cole, Ian Pavord, William W. Busse, Jérôme Msihid, (unknown), Xavier Soler, Amr Radwan, Asif Khan, (unknown), Juby A. Jacob‐Nara	2
5	Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma 2023 ·Allergy ·Nikolaos G. Papadopoulos, Stanley J. Szefler, Leonard B. Bacharier, Jorge Máspero, Christian Domingo, Alessandro Fiocchi, Jason K. Lee, Nadia Daizadeh, David J. Lederer, Megan Hardin, (unknown), Michel Djandji, Shahid Siddiqui, Juby A. Jacob‐Nara, Yamo Deniz, Paul J. Rowe	16
6	Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial 2023 ·Journal of Asthma and Allergy ·Jorge Máspero, Asif Khan, Carl Philpott, Peter W. Hellings, Claire Hopkins, Martin Wagenmann, Shahid Siddiqui, Jérôme Msihid, Scott D. Nash, Chien‐Chia Chuang, Siddhesh Kamat, Paul J. Rowe, Yamo Deniz, Juby A. Jacob‐Nara	9
7	Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization 2023 ·Journal of Asthma and Allergy ·Jonathan Corren, David J. Jackson, Thomas B. Casale, Larry Borish, Klaus F. Rabe, William W. Busse, Jorge Máspero, Daniel J. Jackson, Nadia Daizadeh, Arman Altincatal, Amr Radwan, (unknown), Michel Djandji, Juby A. Jacob‐Nara, Paul J. Rowe, Yamo Deniz	4
8	Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study 2023 ·Respiratory Medicine ·Κonstantinos Κostikas, Jorge Máspero, Kenneth R. Chapman, Karen Mezzi, Xavier Jaumont, David Lawrence, Richard N. van Zyl-Smit	3
9	Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses 2023 ·Pulmonary Therapy ·Richard N. van Zyl-Smit, Huib A.M. Kerstjens, Jorge Máspero, (unknown), David Lawrence, Karen Mezzi, Peter D’Andrea, Kenneth R. Chapman	2
10	The use of systemic corticosteroids in asthma management in Latin American countries 2023 ·World Allergy Organization Journal ·Jorge Máspero, Ãlvaro A. Cruz, (unknown), (unknown), (unknown), (unknown), (unknown)	6
11	Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction 2022 ·Annals of Allergy Asthma & Immunology ·Nicola A. Hanania, Mario Castro, Eric D. Bateman, Ian Pavord, Alberto Papi, J. Mark FitzGerald, Jorge Máspero, Constance H. Katelaris, Dave Singh, Nadia Daizadeh, Arman Altincatal, (unknown), Xavier Soler, Shahid Siddiqui, Elizabeth Laws, Juby A. Jacob‐Nara, Paul J. Rowe, David J. Lederer, Megan Hardin, Yamo Deniz	8
12	Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose 2022 ·The Journal of Allergy and Clinical Immunology In Practice ·Christian Domingo, Jorge Máspero, Mario Castro, Nicola A. Hanania, Linda B. Ford, David Halpin, David J. Jackson, Nadia Daizadeh, Michel Djandji, Colin Mitchell, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Paul J. Rowe, Benjamin Ortiz	11
13	Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON) 2020 ·Respiratory Medicine ·Christian Geßner, Oliver Kornmann, Jorge Máspero, Richard N. van Zyl-Smit, Matthias Krüll, (unknown), Pritam Gupta, (unknown), (unknown), Lorena Garcia Conde, Pascal Pfister	52
14	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma 2018 ·Journal of Allergy and Clinical Immunology ·Sumita Khatri, Wendy C. Moore, Peter G. Gibson, Richard Leigh, Arnaud Bourdin, Jorge Máspero, (unknown), Roland Buhl, Peter Howarth, Frank C. Albers, Eric Bradford, M Gilson, Robert G. Price, Steven W. Yancey, Héctor Ortega	219
15	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials breakdown → 2015 ·The Lancet Respiratory Medicine ·Mario Castro, James Zangrilli, Michael E. Wechsler, Eric D. Bateman, Guy Brusselle, Philip G. Bardin, Kevin Murphy, Jorge Máspero, Christopher O’Brien, Stephanie Korn	840
16	Growth Velocity Reduced with Once-Daily Fluticasone Furoate Nasal Spray in Prepubescent Children with Perennial Allergic Rhinitis 2014 ·The Journal of Allergy and Clinical Immunology In Practice ·Laurie A. Lee, Richard K. Sterling, Jorge Máspero, (unknown), Anna Ellsworth, Søren Pedersen	29
17	Long-Term Safety of Mometasone Furoate/Formoterol Combination for Treatment of Patients with Persistent Asthma 2010 ·Journal of Asthma ·Jorge Máspero, Hendrik Nolte, Iván Chérrez-Ojeda, (unknown)	32
18	Safety and Tolerability of Fluticasone Furoate Nasal Spray Once Daily in Paediatric Patients Aged 6–11 Years with Allergic Rhinitis 2009 ·Clinical Drug Investigation ·Eli O. Meltzer, (unknown), Jorge Máspero, Wei Wu, (unknown)	21
19	What is an Allergist?: Reconciled Document Incorporating Member Society Comments 2008 ·Del Giacco Gs, Lanny J. Rosenwasser, (unknown), Anthony J. Frew, Michael Kaliner, (unknown), Guanghui Liu, Jorge Máspero, Ji‐Yong Moon, (unknown), Paul C. Potter, Anand B. Singh, Erkka Valovirta, D. Vervloët, John O. Warner, (unknown)	1
20	A 12‐week placebo‐controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis 2008 ·Allergy ·(unknown), Jorge Máspero, Catherine Bisbal, Ioana Agache, (unknown), Javier Borja, (unknown), Iñaki Izquierdo, (unknown)	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact